Answers are grounded in this paper and cite their sources.
Fourteen (hetero-)(arylidene)arylhydrazide derivatives ( ABH1 – ABH14 ) were synthesized, and their inhibitory activities against monoamine oxidases (MAOs) and acetylcholinesterase (AChE) were evaluated. Compound ABH5 most potently inhibited MAO-B with an IC 50 value of 0.025 ± 0.0019 μM; ABH2 and ABH3 exhibited high IC 50 values as well. Most of the compounds weakly inhibited MAO-A, except ABH5 (IC 50 = 3.31 ± 0.41 μM). Among the active compounds, ABH2 showed the highest selectivity index (SI) of 174 for MAO-B, followed by ABH5 (SI = 132). ABH3 and ABH5 effectively inhibited AChE with IC 50 values of 15.7 ± 6.52 and 16.5 ± 7.29 μM, respectively, whereas the other compounds were weak inhibitors of AChE. ABH5 was shown to be a reversible competitive inhibitor for MAO-A and MAO-B with K i values of 0.96 ± 0.19 and 0.024 ± 0.0077 μM, respectively, suggesting that this molecule can be considered as an interesting candidate for further development as a multitarget inhibitor relating to neurodegenerative disorders.
No takes yet. Share an insight, caveat, or question.
Palakkathondi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: